pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
Kailera Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Kailera Therapeutics.
Kailera Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Dextromethorphan HBr
Galera Therapeutics
Healthy
1 trial -
GC4419
Galera Therapeutics
Healthy Volunteers
1 trial -
GC4419
Galera Therapeutics
Renal Impairment
1 trial -
GC4419
Galera Therapeutics
Squamous Cell Carcinoma of the Oral Cavity
1 trial -
GC4419 IV
Galera Therapeutics
Healthy Volunteers
1 trial -
GC4702 dry powder
Galera Therapeutics
Healthy Volunteer
1 trial -
GC4711 30 mg IV
Galera Therapeutics
Healthy Volunteers
1 trial -
GC4711 30mg
Galera Therapeutics
Healthy
1 trial -
GC4711 Oral Capsule G-101
Galera Therapeutics
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does Kailera Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.